Colgate-Palmolive director receives stock and option grants

COLGATE PALMOLIVE CO director Brian Newman reported routine equity awards.

Rhea-AI Filing Summary

COLGATE PALMOLIVE CO director Brian Newman reported routine equity awards. He received an annual director stock grant of 2,075 shares of common stock, bringing his direct holdings to 7,621 shares. These shares were granted under the company’s incentive compensation plan.

Newman was also granted stock options for 2,424 shares at an exercise price of $86.7400 per share, expiring on May 11, 2034. The options become exercisable in equal annual installments over three years starting on the first anniversary of the May 11, 2026 grant date. In addition, 36 shares are held indirectly through a family trust.

Insider Trade Summary

Grant/Award: 4,499 shares

Grant/Award 3 txns

Insider Newman Brian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,424	$0.00	$0.00
Grant/Award	Common Stock	2,075	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 2,424 contracts (Direct); Common Stock — 7,621 shares (Direct); Common Stock — 36 shares (Indirect, By Family Trust)

Footnotes (3)

1. F1. Annual director stock grant under the issuer's incentive compensation plan.
2. F2. Annual director stock option grant under the issuer's incentive compensation plan.
3. F3. Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date.

Key Figures

Common stock grant: 2,075 shares Stock options granted: 2,424 options Option exercise price: $86.7400 per share +3 more

6 metrics

Common stock grant 2,075 shares Annual director stock grant on May 11, 2026

Stock options granted 2,424 options Director stock option grant on May 11, 2026

Option exercise price $86.7400 per share Stock option (right to buy) grant

Option expiration date May 11, 2034 Expiration of director stock options

Direct shares after grant 7,621 shares Total common stock directly held after transactions

Indirect shares via family trust 36 shares Common stock held indirectly by family trust

Key Terms

Annual director stock grant, stock option, incentive compensation plan, Family Trust

4 terms

Annual director stock grant financial

"Annual director stock grant under the issuer's incentive compensation plan."

stock option financial

"Annual director stock option grant under the issuer's incentive compensation plan."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

incentive compensation plan financial

"Annual director stock grant under the issuer's incentive compensation plan."

An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.

Family Trust financial

"36.0000 indirect shares reported as By Family Trust."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Colgate-Palmolive (CL) director Brian Newman report in this Form 4?

Brian Newman reported receiving equity compensation awards, not open-market trades. He was granted 2,075 shares of common stock and stock options for 2,424 shares as part of Colgate-Palmolive’s incentive compensation plan, reflecting standard director compensation rather than buy or sell decisions.

How many Colgate-Palmolive (CL) shares does Brian Newman hold after these grants?

After the grants, Brian Newman directly holds 7,621 shares of Colgate-Palmolive common stock. The filing also shows 36 additional shares held indirectly through a family trust, giving investors visibility into both his direct and indirect equity stake reported in this Form 4.

What are the terms of Brian Newman’s new Colgate-Palmolive stock options?

Newman received options on 2,424 shares with an exercise price of $86.7400 per share. These stock options expire on May 11, 2034 and become exercisable in equal annual installments over three years, beginning on the first anniversary of the May 11, 2026 grant date.

Are Brian Newman’s Colgate-Palmolive Form 4 transactions open-market buys or sells?

The reported transactions are equity grants, not open-market buys or sells. The Form 4 shows an annual director stock grant of 2,075 shares and an annual director stock option grant for 2,424 shares, both under Colgate-Palmolive’s incentive compensation plan as compensation rather than trading activity.

How do Brian Newman’s new equity awards at Colgate-Palmolive vest?

The stock options for 2,424 shares vest in equal annual installments over three years. Vesting begins on the first anniversary of the May 11, 2026 grant date, meaning portions of the award become exercisable each year, aligning director compensation with longer-term service at Colgate-Palmolive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 04:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Newman Brian

(Last) (First) (Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		A(1)		2,075	A	$0.0000	7,621	D
Common Stock								36	I	By Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$86.74	05/11/2026		A(2)		2,424		(3)	05/11/2034	Common Stock	2,424	$0.0000	2,424	D

Explanation of Responses:

1. Annual director stock grant under the issuer's incentive compensation plan.

2. Annual director stock option grant under the issuer's incentive compensation plan.

3. Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date.

	/s/ Kristine Hutchinson, Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)